Compare NEO & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | PRCT |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1999 | 2021 |
| Metric | NEO | PRCT |
|---|---|---|
| Price | $13.05 | $31.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $11.38 | ★ $51.13 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 02-17-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,162,000.00 | $299,907,000.00 |
| Revenue This Year | $10.87 | $48.30 |
| Revenue Next Year | $9.84 | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.10 | ★ 50.07 |
| 52 Week Low | $4.72 | $27.80 |
| 52 Week High | $16.18 | $85.00 |
| Indicator | NEO | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 43.13 |
| Support Level | $11.93 | $30.60 |
| Resistance Level | $13.74 | $35.20 |
| Average True Range (ATR) | 0.59 | 1.48 |
| MACD | 0.03 | -0.24 |
| Stochastic Oscillator | 69.46 | 24.57 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.